Nachnani R, Knehans A, Neighbors J, Kocis P, Lee T, Tegeler K
Front Pharmacol. 2024; 15:1282831.
PMID: 38868665
PMC: 11167383.
DOI: 10.3389/fphar.2024.1282831.
Qian L, Beers J, Jackson K, Zhou Z
Pharmaceutics. 2024; 16(4).
PMID: 38675145
PMC: 11054161.
DOI: 10.3390/pharmaceutics16040484.
Czigle S, Nagy M, Mladenka P, Toth J
PeerJ. 2023; 11:e16149.
PMID: 38025741
PMC: 10656908.
DOI: 10.7717/peerj.16149.
Lippert A, Renner B
J Clin Med. 2022; 11(6).
PMID: 35329893
PMC: 8951360.
DOI: 10.3390/jcm11061567.
Lopera V, Rodriguez A, Amariles P
J Clin Med. 2022; 11(5).
PMID: 35268245
PMC: 8911401.
DOI: 10.3390/jcm11051154.
Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes.
Bansal S, Paine M, Unadkat J
Drug Metab Dispos. 2022; 50(4):351-360.
PMID: 35115300
PMC: 11022902.
DOI: 10.1124/dmd.121.000734.
A New Data Repository for Pharmacokinetic Natural Product-Drug Interactions: From Chemical Characterization to Clinical Studies.
Birer-Williams C, Gufford B, Chou E, Alilio M, VanAlstine S, Morley R
Drug Metab Dispos. 2020; 48(10):1104-1112.
PMID: 32601103
PMC: 7543481.
DOI: 10.1124/dmd.120.000054.
A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics.
Cox E, Maharao N, Patilea-Vrana G, Unadkat J, Rettie A, McCune J
Pharmacol Ther. 2019; 201:25-38.
PMID: 31071346
PMC: 6708768.
DOI: 10.1016/j.pharmthera.2019.05.001.
A Review of Cannabis in Chronic Kidney Disease Symptom Management.
Ho C, Martinusen D, Lo C
Can J Kidney Health Dis. 2019; 6:2054358119828391.
PMID: 30828459
PMC: 6388458.
DOI: 10.1177/2054358119828391.
Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.
Anderson G, Chan L
Clin Pharmacokinet. 2016; 55(11):1353-1368.
PMID: 27106177
DOI: 10.1007/s40262-016-0400-9.
Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.
Devereux G, Cotton S, Barnes P, Briggs A, Burns G, Chaudhuri R
Trials. 2015; 16:267.
PMID: 26058585
PMC: 4465017.
DOI: 10.1186/s13063-015-0782-2.
[Not Available].
Matte J, Lapointe M, Lebel M
Can Fam Physician. 2011; 28:111-5.
PMID: 21289851
PMC: 2306292.
Cigarette smoking enhances the elimination of quinine.
Wanwimolruk S, Wong S, Coville P, Viriyayudhakorn S, Thitiarchakul S
Br J Clin Pharmacol. 1993; 36(6):610-4.
PMID: 12959282
PMC: 1364670.
DOI: 10.1111/j.1365-2125.1993.tb00424.x.
Drug interactions with tobacco smoking. An update.
Zevin S, Benowitz N
Clin Pharmacokinet. 1999; 36(6):425-38.
PMID: 10427467
DOI: 10.2165/00003088-199936060-00004.
Marijuana. Respiratory tract effects.
Van Hoozen B, Cross C
Clin Rev Allergy Immunol. 1997; 15(3):243-69.
PMID: 9358987
DOI: 10.1007/BF02737700.
Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.
Troger U, Meyer F
Clin Pharmacokinet. 1995; 28(4):287-314.
PMID: 7648758
DOI: 10.2165/00003088-199528040-00003.
Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
Ha H, Chen J, Freiburghaus A, Follath F
Br J Clin Pharmacol. 1995; 39(3):321-6.
PMID: 7619675
PMC: 1365010.
DOI: 10.1111/j.1365-2125.1995.tb04455.x.
Theophylline kinetics in relation to age: the importance of smoking.
Cusack B, Kelly J, Lavan J, Noel J, OMalley K
Br J Clin Pharmacol. 1980; 10(2):109-14.
PMID: 7426272
PMC: 1430051.
DOI: 10.1111/j.1365-2125.1980.tb01726.x.
Influence of age on theophylline clearance in patients with chronic obstructive pulmonary disease.
Bauer L, Blouin R
Clin Pharmacokinet. 1981; 6(6):469-74.
PMID: 7318306
DOI: 10.2165/00003088-198106060-00005.
Antipyrine kinetics in cannabis smokers.
Uppal R, Garg S, Sharma P, Varma V, Chaudhury R
Br J Clin Pharmacol. 1981; 11(5):522-3.
PMID: 7272166
PMC: 1401589.
DOI: 10.1111/j.1365-2125.1981.tb01162.x.